UNSPSC 51343110: Lamivudine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but generally known as lamivudine, which bears US NIH Compound Identifier 60825. European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG.

UNSPSC 51343110 Lamivudine, a Commodity code, represents antiretroviral pharmaceutical products purchased by state and local health agencies. The source shows no recent open solicitations or active procurement activity tagged to this code. The two opportunities present in the record—an Illinois Department of Public Health pharmaceutical warehouse piggyback contract awarded to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida procurement for Naloxone and Safe Drug Deactivation Systems—are unrelated to lamivudine and do not reflect actual buying activity under this code.

The mismatch between the code's nominal scope and the opportunities presented in the source suggests that this Commodity code carries minimal recent activity at the state and local level, or that tagging inconsistencies have obscured any legitimate procurement records. No issuing-body mix, geographic concentration, or representative recent solicitations applicable to lamivudine procurement can be established from the available data.